Lasater EA, Amin DN, Bannerji R, Mali RS, et al. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R NHL: Results from preclinical models and a Phase Ib study. Am J Hematol 2023 Jan 2. doi: 10.1002/ajh.26809.
PMID: 36594167